Synergy Pharmaceuticals Inc fka SGYPQ

[Opti Mist]

https://seekingalpha.com/article/4078903-synergy-pharmaceuticals-oh-frabjous-day?app=1&auth_param=38sjt:1cjbbqh:7b2e39b70092f3b3fef64b39fe2153f0&uprof=45

Conclusion
It is always exciting when a speculative stock has a big up day. When it has several in a row, as was the case with Synergy last week, it is positively exhilarating. This is even more the case when the positive action is reversing a long downward slide.

So it is that Synergy really had my juices flowing these past few days. Now, in the sober light of a long, hot weekend, I am coming to realize that the report on Trulance scrips as reported by BTIG Research's Timothy Chiang is not much of a big deal. Shucks, it doesn't add significantly positive data beyond that often cited in the widely circulated prescription numbers that show up in every Synergy comment stream.
If I ask myself "what's really changed?," I have to answer "not much; maybe nothing." It was a frabjous day indeed, a made-up word describing an event that may prove to be more enervating for Synergy in the near term than invigorating.
The foregoing explains why I am unimpressed. How do I explain my decision to invest in this name? For that I have to move from the short-term framework to the longer term. I am convinced that Trulance will prove its entitlement as best in class for CIC.
I am of the opinion that once it does so over a period of years it will find significant profitable revenues not just in the United States, but around the Commonwealth, Europe, the Middle East, Japan and China. Accordingly, its frabjous day may be meaningless. But its fabulous potential is anything but meaningless.